POM-V Prescription Required

Butagran Equi 200 mg/g Oral Powder for Horses

Active ingredient: Phenylbutazone

Form

Powder

Species

Horses

Manufacturer

Dopharma Research B.V.

VMD MA No.

28365/4004

What it's used for

and soft tissue inflammation, particularly where continued mobility is considered desirable. It is also of value in limiting post-surgical inflammation, my...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Phenylbutazone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Butagran Equi 200 mg/g Oral Powder for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

and soft tissue inflammation, particularly where continued mobility is considered
desirable.
It is also of value in limiting post-surgical inflammation, myositis and other soft tissue
inflammation.
The veterinary medical product can be used as an anti-pyretic where this is
considered advisable e.g. in viral respiratory infections.

For each 450 kg of body weight the following dosage guide should be used
according to individual response:
Day 1: Two sachets or 10 g of veterinary medicinal product twice daily (equivalent to
4.4 mg of phenylbutazone/kg of BW on each occasion).
Day 2-4: One sachet or 5 g of veterinary medicinal product twice daily (equivalent to
2.2 mg of phenylbutazone/kg of BW on each occasion) followed by one sachet or 5 g
of veterinary medicinal product daily (2.2 mg of phenylbutazone/kg of BW daily) or
on alternate days as required.
If no response is evident after 4-5 days, discontinue treatment. Hay may delay the
absorption of phenylbutazone and so the onset of a clinical effect. It is advisable not
to administer hay immediately prior to, or during the administration of the veterinary
medicinal product.
For ease of administration the veterinary medicinal product may be mixed with a
limited quantity of bran or oats.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
AN: 00118/2025 & 00119/2025
Do not use in animals suffering from cardiac, hepatic or renal disease, where there is
the possibility of gastrointestinal ulceration or bleeding or where there is evidence of
a blood dyscrasia.

Horses:
Rare
(1 to 10 animals / 10,000
animals treated):
Gastric irritation
Renal disorder
Undetermined frequency
(cannot be estimated from the
available data):
Blood dyscrasia
Gastric ulceration
Diarrhoea
Oral ulceration
Hypoproteinaemia
1
Usually associated with overdosage. Recovery is usual on cessation of treatment
and following the initiation of supportive symptomatic therapy. See section 3.10.
Ponies are very sensitive, even at therapeutic doses.
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or the national competent authority via
the national reporting system. See the package leaflet for respective contact details.

The clinical effects of phenylbutazone can be evident for at least three days following
cessation of therapy. This should be borne in mind when examining horses for
soundness.

Special precautions for safe use in the target species:
Do not exceed the stated dose as the therapeutic index of phenylbutazone is low.
Use in any animal less than 6 weeks of age or in aged animals may involve
additional risk. If such use cannot be avoided, animals may require careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a
potential risk of increased renal toxicity. Keep water readily available during the
treatment period to avoid dehydration.
Non-steroidal anti-inflammatory drugs (NSAIDs) can cause inhibition of phagocytosis
and hence in the treatment of inflammatory conditions associated with bacterial
infections, appropriate concurrent antimicrobial therapy should be instigated.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
This veterinary medicinal product may cause hypersensitivity (allergic) reaction in
those sensitised to phenylbutazone, either via skin contact or accidental ingestion.
People with known hypersensitivity to phenylbutazone should avoid contact with the
veterinary medicinal product.
If you develop symptoms following exposure, such as a skin rash, you should seek
medical advice and show the doctor this warning. Swelling of the face, lips or eyes,
or difficulty breathing, are more serious symptoms and require urgent medical
attention.
This veterinary medicinal product can be irritating to the skin and the eyes. Avoid
contact with the eyes. In case of accidental eye contact, irrigate eyes with plenty of
clean water. If irritation persists, seek medical advice.
Care should be taken to avoid inhaling or ingesting the powder. In case of accidental
inhalation or ingestion, seek medical advice immediately and show the package
leaflet or the label to the physician.
Wash any exposed skin and hands after use.
Special precautions for the protection of the environment:
Not applicable.
AN: 00118/2025 & 00119/2025

Concurrent administration of potential nephrotoxic drugs should be avoided.
Phenylbutazone is extensively bound to plasma proteins. It may displace other drugs
that are highly protein-bound e.g. some sulphonamides, warfarin or it may itself be
displaced to produce an increase in non-bound pharmacologically active
concentrations, which can lead to toxic effects.
Concurrent therapy with other therapeutic agents should be undertaken with caution
due to the risk of metabolic interactions. Phenylbutazone may interfere with the
metabolism of other drugs e.g. warfarin, barbiturates, with resultant toxicity.
There is evidence to indicate that the pharmacokinetics of penicillin and gentamicin
products may be affected by concurrent administration of products containing
phenylbutazone with a possible reduction of therapeutic efficacy, since tissue
penetration may be reduced. The distribution of other drugs given concurrently may
also be affected.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Phenylbutazone induces hepatic microsomal enzyme activity.

Do not store above 25 °C.
Keep the sachets in the outer carton.

Not for use in horses intended for human consumption. Not for use in mares
producing milk for human consumption.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.